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Abstract
Background: Cerebrospinal fluid (CSF) lactate is frequently used as a biomarker in
humans with inflammatory central nervous system (CNS) disorders including bacterial
meningitis and autoimmune disorders such as multiple sclerosis.
Hypothesis: Cerebrospinal fluid lactate concentrations are increased in a subset of
dogs with inflammatory CNS disorders.
Animals: One hundred two client-owned dogs diagnosedwith inflammatory CNS disease.
Methods: Case series. Cases were identified both prospectively at the time of diagno-
sis and retrospectively by review of a CSF biorepository. Cerebrospinal fluid lactate
was analyzed with a commercially available, handheld lactate monitor. Subcategories
of inflammatory disease were created for comparison (eg, steroid-responsive meningi-
tis arteritis, meningoencephalitis of unknown etiology).
Results: Cerebrospinal fluid lactate concentrations were above reference range in
47% of dogs (median, 2.5 mmol/L; range, 1.0-11.7 mmol/L). There was no significant
difference in lactate concentrations between disease subcategories (P = .48). Signifi-
cant but weak correlations were noted between CSF lactate concentration and nucle-
ated cell count (r = .33, P < .001), absolute large mononuclear cell count (r = .44,
P < .001), absolute small mononuclear cell count (r = .39, P < .001), absolute neutrophil
cell count (r = .24, P = .01), and protein (r = .44, P < .001). No correlation was found
between CSF lactate concentration and CSF red blood cell count (P = .58). There was
no significant association of CSF lactate concentration with survival (P = .27).
Conclusions and Clinical Importance: Cerebrospinal fluid lactate concentrations
could serve as a rapid biomarker of inflammatory CNS disease in dogs.
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1 | INTRODUCTION
Cerebrospinal fluid (CSF) lactate is being increasingly evaluated as a
potential biomarker of central nervous system (CNS) disease in dogs.
Normative data and reference intervals for CSF lactate concentrations
have been reported in dogs.1-4 There are increases in CSF lactate con-
centrations in dogs with severe cognitive deficits,5 and a trend to
increasing values was noted in dogs with intracranial disease.1 How-
ever, another study failed to detect a difference in CSF lactate values
between dogs with or without structural intracranial disease.6 Outside
these few studies performed in small numbers of dogs, there is little
information available related to CSF lactate in diseased dogs.
In humans, CSF lactate concentrations are increased in a variety
of CNS disorders including mitochondrial disorders, inflammatory con-
ditions, head trauma, and seizures.7-11 Perhaps, the greatest utility in
humans is to distinguish bacterial from aseptic meningitis.12,13 How-
ever, lactate concentrations are also increased in some patients with
presumed autoimmune inflammatory conditions such as neuromyelitis
optica14 and multiple-sclerosis.15-18
Recently, a handheld lactate monitor has been validated for quan-
tification of L-lactate in canine blood and CSF and a CSF reference
interval for this analyte has been established (1.02-2.49 mmol/L).4,19
The purpose of this study was to evaluate CSF lactate concentrations
in dogs with inflammatory CNS diseases. We hypothesized that many
of these CSF samples would have lactate concentrations above the
upper end of our established reference interval.
2 | MATERIALS AND METHODS
2.1 | Animals, CSF sample collection, CSF analysis
and outcome determination
Dogs that were referred to the NC State Veterinary Hospital for a
variety of presenting complaints were included in the study. Inclusion
criteria were CNS imaging (magnetic resonance imaging [MRI] or com-
puted tomography [CT], with the exception of dogs diagnosed with
steroid-responsive meningitis-arteritis [SRMA], see below), routine CSF
analysis (nucleated and red blood cell counts, protein evaluation, and
cytological evaluation), a clinical diagnosis of inflammatory CNS disease
(see Diagnostic Groups below), and a complete medical record. Cerebro-
spinal fluid samples were collected as part of a routine diagnostic evalua-
tion from the cerebellomedullary cistern or lumbar subarachnoid space.
Informed, written client consent was obtained for the use of these
samples for research purposes. Most samples were analyzed within
5 minutes of collection with a commercially available lactate monitor
(Lactate Plus; Nova Biomedical,Waltham,Massachusetts) although some
were evaluated after being frozen at−80C.
The age at presentation, sex, breed, weight, clinical lesion localiza-
tion, CSF collection site, CSF nucleated cell count, CSF red blood cell
count, CSF protein, CSF cytological evaluation (percentage of small
mononuclear cells, large mononuclear cells, neutrophils, and other
cells), and CSF lactate concentration were recorded. In dogs with CSF
collected from both the cerebellomedullary cistern and the lumbar
subarachnoid space, CSF obtained from the site closest to the identi-
fied lesion was used for analysis. The CSF nucleated cell count was
multiplied by the proportion of large mononuclear cells, small mono-
nuclear cells, and neutrophils seen on cytological evaluation to gener-
ate absolute cell counts for each CSF sample.
Dogs could have normal CNS imaging or CSF analysis but had to
have consistent abnormalities in 1 of these diagnostic tests in order to
be included. Further inclusion criteria for imaging and CSF results are
described below. Cases were excluded if CNS imaging revealed a
well-defined, focal mass lesion or a parenchymal lesion in a distribu-
tion compatible with a cerebrovascular ischemic injury. Dogs were
assigned to specific diagnostic groups based on clinical criteria includ-
ing signalment, clinical signs, and diagnostic testing. The criteria for
diagnosis of specific inflammatory CNS conditions are listed in more
detail below.
The medical record was reviewed to determine if dogs survived to
hospital discharge and in dogs that died spontaneously or underwent
euthanasia, and the date of death was recorded. For dogs that were
still alive at the last recorded visit, dog owners, referring veterinarians,
or both were contacted to determine if the dog was still alive and if
not, the date of death. The results of necropsy examinations were also
recorded when available.
2.2 | Diagnostic groups
2.2.1 | Granulomatous meningoencephalitis,
necrotizing meningoencephalitis, and necrotizing
leukoencephalitis
These diagnoses were made after histological evaluation of the brain,
cervical spinal cord, or both regions according to published reports.20,21
2.2.2 | Meningoencephalitis of unknown etiology
This diagnosis was made in dogs with suspected granulomatous menin-
goencephalitis (GME), necrotizing meningoencephalitis (NME), or nec-
rotizing leukoencephalitis (NLE) but in which histopathology of the
nervous system was not performed. In these cases, the diagnosis was
based on CNS imaging and CSF evaluation.22 Imaging typically showed
multifocal hyperintense lesions on T2-weighted and fluid-attenuated
inversion recovery (FLAIR) imaging, with variable degrees of meningeal
and parenchymal enhancement after IV administration of contrast
(gadoversetamide, 0.1 mmol/kg [Optimark, Mallinckrodt Inc, St. Louis,
Missouri] or iohexol, 2.2 mL/kg [Omnipaque 350 mgI/mL, GE
Healthcare, Marlborough, Massachusetts]). Diffuse, ill-defined T2 and
FLAIR hyperintense lesions were also noted. Cerebrospinal fluid evalua-
tion typically showed a mononuclear pleocytosis. However, as a signifi-
cant proportion of dogs with meningoencephalitis of unknown etiology
(MUE) lack a pleocytosis and some dogs have a marked pleocytosis in
the absence of imaging changes, an MUE diagnosis could be made with
only imaging or CSF criteria.23,24 Infectious disease testing varied some-
what in this cohort but was negative in all cases.
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2.2.3 | Meningomyelitis
These cases were similar to MUE cases but with primary involvement
of the spinal cord.
2.2.4 | Total MUE
As MUE is a clinical term used to indicate dogs suspected to have
GME, NME, or NLE that do not have a histological diagnosis and many
use the term MUE to encompass dogs with spinal cord involvement,
dogs in the MUE, GME/NME/NLE, and meningomyelitis groups were
combined to create this group.
2.2.5 | Steroid-responsive meningitis-arteritis
For inclusion, dogs with SRMA had to be less than 3 years of age at pre-
sentation and had to have cervical pain as their primary clinical sign, with
minimal or no associated neurologic deficits. These dogs also had a CSF
neutrophilic pleocytosis (unless chronically affected) and showed dramatic
clinical improvement after the administration of glucocorticoids. When
measured, these dogs had increased serum concentrations of C-reactive
protein. Imaging of the CNS was not required for this group but if per-
formed was limited to meningeal enhancement after IV administration of
contrast with an absence of parenchymal lesionswithin theCNS.
2.2.6 | Infectious or presumed infectious
meningoencephalitis or meningomyelitis
These dogs had evidence of CNS inflammation together with a positive
test for an infectious disease, which might have included testing of blood
or CSF for antigen, antibody titers, nucleic acids via polymerase chain
reaction-based testing, or microscopic visualization of organisms in a clin-
ical sample. Presumed infectious cases included dogs that had a clinical
response to antibiotic administration without concurrent glucocorticoid
or other anti-inflammatory or immunosuppressivemedications.
2.2.7 | Miscellaneous
This group included dogs with idiopathic tremor syndrome, idiopathic
hypertrophic pachymeningitis, eosinophilic meningoencephalitis, and 1
dog with a histologically confirmed infiltrative inflammatory condition
involving the paraspinal musculature, meninges, and cervical spinal cord.
2.3 | Statistical analysis
Descriptive statistics were generated for age at presentation, weight,
CSF nucleated cell counts, CSF red blood cell count, CSF protein, and
CSF lactate concentration. A D'Agostino and Pearson normality test
showed that the lactate values did not follow a normal distribution
and therefore nonparametric evaluations were used to compare diag-
nostic groups. A Kruskal-Wallis test was used to compare lactate
values between diagnostic groups. A Spearman correlation was used
to examine the relationships between CSF parameters and lactate
concentrations and between lactate concentrations and survival. Sur-
vival times were calculated from the date of CSF collection. Survival
curves were constructed using the Kaplan-Meier method and compared
using a log-rank test. Dogs that were still alive or lost to follow-up were
censored at the last available contact date. Lactate concentrations of
dogs that did or did not survive to be discharged from the hospital were
compared using a Mann-Whitney test, and this test was also used to
compare survival times in dogs with lactate concentrations within or
above the reference interval. A P value < .5 was considered significant.
All analyses were conducted using Prism (Version 7, GraphPad Soft-
ware, Inc, La Jolla, California).
3 | RESULTS
A total of 102 dogs with a diagnosis of inflammatory CNS disease
were included, with a variety of breeds represented. Descriptive sta-
tistics for individual diagnostic groups and the whole cohort are
shown in Table 1. Lesions were localized to the following locations:
TABLE 1 Characteristics of dogs categorized in different inflammatory CNS groups
Number of dogs Age (years) Weight (kg)
Sex
Diagnostic category M MC F FS
GME/NME/NLE 8 7.6 (2.4-10.0) 19.3 (2.9-30.6) 1 3 0 4
MUE 44 6.1 (0.8-14.7) 6.7 (2.5-33.0) 2 15 0 27
Meningomyelitis 17 6.9 (1.8-11.9) 11.3 (2.0-32.4) 1 7 1 8
TMUE 69 6.6 (0.8-14.7) 7.6 (2.0-33.0) 4 25 1 39
SRMA 14 0.7 (0.4-1.5) 22.4 (10.0-29.1) 3 5 3 3
Suspect infectious 12 2.1 (0.1-10.8) 15.45 (2.0-34.6) 2 1 3 6
Miscellaneous 7 5.0 (1.5-11.0) 10.5 (6.2-30.6) 1 1 1 4
All cases 102 5.6 (0.1-14.7) 10.7 (2.0-34.6) 10 32 8 52
Age and weight values are expressed as median (range).
Abbreviations: CNS, central nervous system; FS, female spayed; GME, granulomatous meningoencephalitis; MC, male castrated; MUE, meningoencephalitis
of unknown etiology; NLE, necrotizing leukoencephalitis; NME, necrotizing meningoencephalitis; SRMA, steroid-responsive meningitis-arteritis; TMUE,
total MUE.
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forebrain in 15 dogs (14.7%), brainstem in 16 dogs (15.7%), cerebel-
lum in 4 dogs (3.9%), cervical myelopathy or cervical pain in 28 dogs
(27.5%), thoracolumbar myelopathy in 5 dogs (4.9%), diffuse spinal
pain in 3 dogs (2.9%), and multifocal CNS in 31 dogs (30.1%).
Magnetic resonance imaging was performed in 92 dogs (90.2%), CT in
5 dogs (4.9%), 1 dog (1.0%) was imaged with both modalities, and
TABLE 2 Cerebrospinal fluid variables in dogs with inflammatory CNS disease
Collection site
Nucleated cell count (cells/μL) Red blood cell count (cells/μL) Protein (mg/dL)Diagnostic category CCSF LCSF
GME/NME/NLE 7 1 237.5 (7-1702) 201 (3-533) 203.1 (36.0-981.5)
MUE 35 9 67 (0-5320) 41 (0-12 100) 60.5 (1.4-915.0)
Meningomyelitis 12 5 176 (1-1160) 45 (0-12 800) 138.8 (26.2-537.5)
TMUE 54 15 130 (0-5320) 43 (0-12 800) 83.6 (1.4-981.5)
SRMA 13 1 897.5 (4-5267) 1069 (25-40 000) 102.1 (25.9-318.9)
Suspect infectious 9 3 119 (3-1773) 23 (0-1440)* 57.7 (15.6-958.0)
Miscellaneous 7 0 7 (3-1002) 20 (3-1833) 34.0 (12.6-225.3)
All cases 83 19 133.5 (0-5320) 45 (0-40 000) 83.1 (1.4-981.5)
Nucleated cell count, red blood cell count, and protein values are expressed as median (range).
Abbreviations: CNS, central nervous system; CCSF, cerebellomedullary cistern cerebrospinal fluid; GME, granulomatous meningoencephalitis; LCSF,
lumbar subarachnoid space cerebrospinal fluid; MUE, meningoencephalitis of unknown etiology; NLE, necrotizing leukoencephalitis; NME, necrotizing
meningoencephalitis; SRMA, steroid-responsive meningitis-arteritis; TMUE, total MUE.
*In 1 sample, the red cell count was not available.
TABLE 3 Cerebrospinal fluid lactate concentrations in dogs with inflammatory CNS disease
Diagnostic category Number
Median lactate
(range) (mmol/L)
Mean lactate
(mmol/L)
Samples above
reference interval (%)a
GME/NME/NLE 8 2.5 (2.1-7.0) 3.7 4 (50)
MUE 44 2.45 (1.0-8.4) 2.9 20 (45)
Meningomyelitis 17 2.7 (1.3-6.6) 2.9 10 (59)
TMUE 69 2.5 (1.0-8.4) 3.0 34 (49)
SRMA 14 2.1 (1.1-4.9) 2.4 6 (43)
Suspect infectious 12 2.6 (1.0-11.7) 3.1 6 (50)
Miscellaneous 7 1.9 (1.5-4.1) 2.2 2 (29)
All cases 102 2.5 (1.0-11.7) 2.9 48 (47.1)
Abbreviations: CNS, central nervous system; GME, granulomatous meningoencephalitis; MUE, meningoencephalitis of unknown etiology; NLE, necrotizing
leukoencephalitis; NME, necrotizing meningoencephalitis; SRMA, steroid responsive meningitis-arteritis; TMUE, total MUE.
aReference interval is 1.02-2.49 mmol/L.
TABLE 4 Survival in dogs with inflammatory CNS disease
Diagnostic category Number Whole cohort
Median survival (range) (days)
Lactate within reference interval
Lactate above
reference interval
GME/NME/NLE 8 1 (1-843) 1 (1-1) 1 (1-843)
MUE 44 Not reacheda (1-2433) Not reached (1-1674) 839 (1-2433)
Meningomyelitis 17 439 (5-2225) 520 (5-601) 302 (6-2225)
TMUE 69 839 (1-2433) Not reached (1-1674) 839 (1-2433)
SRMA 14 Not reached (7-1720) Not reached (7-1720) 549 (165-744)
Suspect infectious 12 170 (1-500) 170 (1-500) Not reached (1-463)
Miscellaneous 7 Not reached (1-651) Not reached (1-651) 72 (1-143)
All cases 102 843 (1-2433) Not reached (1-1720) 839 (1-2433)
Abbreviations: CNS, central nervous system; GME, granulomatous meningoencephalitis; MUE, meningoencephalitis of unknown etiology; NLE, necrotizing
leukoencephalitis; NME, necrotizing meningoencephalitis; SRMA, steroid-responsive meningitis-arteritis; TMUE, total MUE.
aThe median survival time was not reached in some groups where >50% of animals were still alive.
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4 dogs (3.9%) with SRMA did not have advanced CNS imaging. Eighty-
three CSF samples (81.4%) were collected from the cerebellomedullary
cistern, and 19 (18.6%) from the lumbar subarachnoid space. Characteris-
tics of the CSF analysis for each diagnostic group are shown in Table 2.
Due to limited sample volume, total protein concentration was not avail-
able for 5 cases. A total of 90/102 (88.2%) dogs had pleocytosis and
78/97 (80.4%) dogs had increased CSF protein concentrations.
The CSF lactate results are shown in Table 3. There was only
1 dog with a confirmed diagnosis of bacterial meningitis, and the lac-
tate concentration was 11.7 mmol/L. There was no significant difference
in lactate concentrations between the diagnostic groups (P = .48) and no
obvious relationship between lactate and breed (data not shown). Signifi-
cant butweak correlationswere noted betweenCSF lactate concentration
and nucleated cell count (r = .33, P < .001), absolute largemononuclear cell
count (r = .44, P < .001), absolute small mononuclear cell count (r = .39,
P < .001), absolute neutrophil cell count (r = .24, P = .01), and protein
(r = .44, P < .001). No correlation was found between CSF lactate concen-
tration and red blood cell count (P = .58).
Eighty-one of 102 dogs (79.4%) survived to hospital discharge.
Thirty-nine dogs (38.2%) died or were euthanized, and 63 (61.8%)
were censored in the survival analysis. Survival times for the diagnos-
tic groups are shown in Table 4 and Figure 1. When considering all
diagnostic groups, there was a significant difference in survival, but
this was primarily driven by the short survival in the group that had a
histological diagnosis, an obvious confounding factor. When this
group was removed or when the total MUE group was compared with
the non-MUE groups, there was no significant difference in survival
(P = .31). There was no correlation between lactate concentration and
overall survival (P = .27) or difference in concentrations between
those dogs that did or did not survive to hospital discharge (P = .58).
In addition, although there was some divergence of the survival cur-
ves (Figure 1), survival was not different between dogs with lactate
concentrations within or above the reference interval (P = .38).
4 | DISCUSSION
We found that 47% of dogs with inflammatory CNS disease had CSF
lactate concentrations above our established reference interval and
that this proportion did not vary substantially between diagnostic
groups. The CSF lactate concentration correlated weakly with CSF
nucleated cell counts and protein but not with red blood cell counts.
Cerebrospinal fluid lactate concentrations were not associated with
overall survival or survival to hospital discharge.
Two prior studies of CSF lactate have been performed in dogs
with intracranial disease with conflicting results.1,6 However, both
studies evaluated small numbers of dogs with a variety of disorders
(11 and 13 dogs with documented structural disease), and it is not sur-
prising that the results varied. Meningoencephalitis was diagnosed in
only 2 and 4 of the dogs in these studies, precluding reasonable com-
parison to our results.
Lactate has been extensively studied in human CSF and is increased
in a number of conditions, including mitochondrial disorders, head
F IGURE 1 Survival curves for (A) the whole cohort of dogs with
inflammatory CNS disease and (B) dogs with MUE, meningomyelitis,
or histologically diagnosed GME, NME, or NLE (TMUE). There was no
difference in survival of dogs with (C) inflammatory CNS disease and
either normal CSF lactate (solid line) or increased CSF lactate (dashed
line) (P = .74) or (D) TMUE dogs with either normal CSF lactate (solid
line) or increased CSF lactate (dashed line) (P = .52). Ticks represent
dogs that were censored during analysis. CNS, central nervous
system; CSF, cerebrospinal fluid; GME, granulomatous
meningoencephalitis; MUE, meningoencephalitis of unknown
etiology; NLE, necrotizing leukoencephalitis; NME, necrotizing
meningoencephalitis; SRMA, steroid responsive meningitis-arteritis;
TMUE, total MUE
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trauma, and inflammatory conditions.8-11 Indeed, one of the greatest
utilities of this analyte is distinguishing bacterial from aseptic meningi-
tis, a common clinical conundrum in humans.12,13 The only dog in our
study with a confirmed diagnosis of bacterial meningitis had a CSF lac-
tate concentration of 11.7 mmol/L. It is also possible that bacterial
infections went undetected in some of the dogs in this study. However,
this seems unlikely as bacteria were not observed on cytological
examination; most samples displayed a mononuclear pleocytosis and
a majority of animals responded favorably to prolonged immunosup-
pressive treatment.
Cerebrospinal fluid lactate is increased in subsets of human patients
with multiple sclerosis (MS), a well-known, immune-mediated inflamma-
tory CNS disorder.15,17,18 This can occur in patients with both primary
progressive and remitting-relapsing forms of the disease, particularly
during exacerbations, relapses, or with secondary progression.17,18
Despite this, a number of MS patients have CSF lactate concentra-
tions within established reference intervals.15,16,25 However, even
when CSF lactate concentrations remain within normal reference
intervals, these concentrations can be higher than those seen in con-
trol groups.16,18 In addition, CSF lactate concentrations have been
correlated with injury severity as measured by progression/disability
scores,16 markers of neuronal damage,16 and the presence of inflam-
matory plaques on MRI.17,25
An increased CSF lactate concentration in MS patients has been
attributed to CNS inflammation. In addition to its correlation with
inflammatory plaques on imaging, Simone et al found that CSF lactate
concentration correlated with CSF mononuclear cell counts.17 Most
of the dogs in this study had a mononuclear pleocytosis, often with a
predominance of small mononuclear cells or lymphocytes. Although
we could demonstrate only a weak correlation between absolute lym-
phocyte count and lactate concentrations and some dogs (primarily in
the SRMA group) with a neutrophilic pleocytosis also had increased
lactate concentrations, it is possible that CSF lactate concentrations
might relate to the activation status of lymphocytes within the CSF in
some dogs. During the rapid proliferation associated with antigenic
stimulation, lymphocytes are known to utilize aerobic glycolysis, which
results in the generation of large amounts of extracellular lactate, a phe-
nomenon known as the Warburg effect.26,27 This phenomenon was
originally described in neoplastic cells and occurs in a variety of cancers,
including lymphoma.28-30 Thus, it is possible that some dogs had an
abundance of actively proliferating lymphocytes within the CSF and
lactate concentrations in these individuals served as a proliferative
marker. This would be supported by our observation that some of the
highest CSF lactate concentrations noted in this study were from dogs
with a marked lymphocytic pleocytosis and those noted to have exten-
sive lymphocyte proliferation within perivascular spaces of the CNS at
necropsy.
Another theory for the increased CSF lactate concentrations
noted in humans with MS is related to impaired energy metabolism
secondary to mitochondrial dysfunction.16,18 Children with CNS dys-
function secondary to inherited mitochondrial disorders are well
documented to have increased CSF lactate.9,10,31 It is possible that
mitochondrial dysfunction is playing a role in dogs with inflammatory
CNS disorders, but this will require further study.
The monitor used in this study requires a small volume of CSF
(.7 μL) to generate an accurate measurement and takes 13 seconds to
complete once testing is initiated. This method has particular utility
for dogs with MUE as these are frequently small or toy breed dogs in
which a limited quantity of CSF can be collected. This paucity of sam-
ple can limit the use of other lactate analyzers, particularly benchtop
units. The short analysis time allows for a rapid, “cage-side” analysis of
CSF lactate, and we have found this to be a useful method of
supporting a presumptive diagnosis of meningoencephalitis before
the results of conventional CSF evaluation are available. This infor-
mation might also facilitate the early initiation of anti-inflammatory
or immunosuppressive therapy in some dogs with severe clinical
signs in which increased intracranial pressure and brain herniation
are concerns.
This study did not find a consistent relationship between CSF lac-
tate and prognosis, looking at either overall survival or survival to hos-
pital discharge. Survival analyses in clinical veterinary patients must
be interpreted cautiously as most dogs experienced euthanasia as
opposed to natural death, which is driven by a number of factors
including owner preferences and financial constraints. This study is no
exception, and it is possible that we were unable to detect a true rela-
tionship between CSF lactate, disease severity, and prognosis due to
these confounding factors.
As previous canine studies showed that blood contamination was
unlikely to alter standard CSF variables with red blood cell counts less
than 13 230 cells/μL32 and human studies have suggested that even
marked blood contamination has no effect on lactate concentrations,33,34
we chose not to exclude cases with red blood cell contamination in this
study. In addition, a preliminary analysis comparing red blood cell counts
and lactate concentrations showed a complete lack of correlation
(n = 102, P = .86, Spearman r = .018), and we further observed that
many substantially blood-contaminated samples had lactate concentra-
tions within the reference interval.
There are several limitations of this study. First, there is some
ambiguity in terms of the diagnoses being made by using clinical
parameters for most cases instead of histopathology. However, we
used well-established clinical guidelines for establishing these diagno-
ses.23,35-37 Additionally, the histopathology group closely resembled
the others in terms of the distribution and range of CSF lactate con-
centrations. Finally, inclusion of a few incorrect diagnoses would be
unlikely to substantially alter the main results or conclusions of the
study. Secondly, we did not account for the potential effect of seizure
activity on CSF lactate concentrations, which has been shown to alter
this analyte in some human studies.38,39 The effect of seizures on CSF
lactate in dogs requires further study. A third limitation relates to the
potential effect of blood lactate on CSF lactate. Prior studies in exper-
imental animals and humans have demonstrated that lactate does not
freely cross the blood-brain or blood-CSF barriers,40-43 and instead
relies on monocarboxylic acid transport systems.44 As a result, blood
and CSF lactate concentrations are relatively independent. Although
there are few studies available in dogs, the prior study that validated
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the Lactate Plus meter for canine CSF showed that although CSF and
blood lactate were correlated, this correlation was very weak.4 There-
fore, although blood lactate concentrations might have influenced
CSF concentrations, we suspect that this influence was minimal.
However, this relationship also warrants further study.
In conclusion, approximately half of all the dogs with inflammatory
CNS disorders as well as those with MUE had increased CSF lactate
concentrations. The Lactate Plus monitor provides a useful method
of obtaining a rapid analysis of this analyte with very small sample
volumes, potentially facilitating the diagnosis of MUE in the hospital.
Cerebrospinal fluid lactate was weakly correlated with CSF nucleated
cell counts and protein but not with red blood cell counts and did not
show a consistent relationship with survival. The mechanisms by
which CSF lactate is increased in dogs with inflammatory CNS disor-
ders might include microbial infection, lymphocyte proliferation, and
mitochondrial dysfunction but require additional study.
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